No

Vaccine

Immunization of persons 2 years of age and above in epidemic or endemic areas as might be determined in a population delineated by neighborhood, school, dormitory, or other reasonable boundary. The prevalent serogroup in such a situation should match a serogroup in the vaccine. Individuals at particular high-risk include persons with terminal component complement deficiencies and those with anatomic or functional asplenia.

Travelers visiting areas of a country that are recognized as having hyperendemic or epidemic meningococcal disease

Vaccinations should be considered for household or institutional contacts of persons with meningococcal disease as an adjunct to appropriate antibiotic chemoprophylaxis as well as medical and laboratory personnel at risk of exposure to meningococcal disease

C

Children <2 years of age

Patients who undergo splenectomy secondary to trauma or nonlymphoid tumors respond well; however, those asplenic patients with lymphoid tumors who receive either chemotherapy or irradiation respond poorly; pregnancy, unless there is substantial risk of infection.

All serious adverse reactions must be reported to the U.S. Department of Health and Human Services (DHHS) Vaccine Adverse Event Reporting System (VAERS) 1-800-822-7967.

Central nervous system: Pain (17.5% to 24%)

Dermatologic: Erythema (0.8% to 31.7%), induration (4.8% to 8.3%)

Local: Tenderness (24% to 29%)

1% to 10%: Central nervous system: Headache (1.2% to 4.1%), malaise ( less than or equal to 2.6%), fever (0.4% to 3.1%), chills ( less than or equal to 1.7%)

Decreased effect with administration of immunoglobulin within 1 month

Discard remainder of vaccine within 5 days after reconstitution; store reconstituted vaccine in refrigerator

Induces the formation of bactericidal antibodies to meningococcal antigens; the presence of these antibodies is strongly correlated with immunity to meningococcal disease caused by Neisseria meningitidis groups A, C, Y and W-135.

Onset: Antibody levels are achieved within 10-14 days after administration

Duration: Antibodies against group A and C polysaccharides decline markedly (to prevaccination levels) over the first 3 years following a single dose of vaccine, especially in children <4 years of age

One dose S.C. (0.5 mL); the need for booster is unknown

Give by S.C. injection; do not administer intradermally, I.M., or I.V.

May cause drowsiness

None reported

No information available to require special precautions

No effects or complications reported

Inform patients about common side effects; patients should report serious and unusual effects to physician

Epinephrine 1:1000 should be available to control allergic reaction

Injection: 10 dose, 50 dose